Total trials
228
Active
76
Phase 3
32
Total enrollment
97,180
Pipeline matrix
Showing 40 of 100 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Sildenafil | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | 8 | |||
| Bevacizumab | — | — | — | — | 3 | ||
| chemotherapy | — | — | — | — | 2 | ||
| Dexamethasone | — | — | — | — | — | 1 | |
| Standard of care plus pembrolizumab | — | — | — | — | — | 1 | |
| Standard of care | — | — | — | — | — | 1 | |
| Sonazoid | — | — | — | — | — | 1 | |
| carboplatin, thiotepa, and cyclophosphamide | — | — | — | — | — | 1 | |
| Intra arterial infusion Floxuridine (FUDR) combined with systemic therapy | — | — | — | — | — | 1 | |
| Systemic therapy | — | — | — | — | — | 1 | |
| Somatostatin analog | — | — | — | — | — | 1 | |
| PTC+Pertuzumab | — | — | — | — | — | 1 | |
| FEC-T+Pertuzumab | — | — | — | — | — | 1 | |
| Hyperthermic Intraperitoneal Chemotherapy | — | — | — | — | — | 1 | |
| ddAC-CP-Olaparib | — | — | — | — | — | 1 | |
| ddAC-mini CTC | — | — | — | — | — | 1 | |
| Carboplatin and Paclitaxel | — | — | — | — | — | 1 | |
| Doxorubicin, cyclophosphamide | — | — | — | — | — | 1 | |
| Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide | — | — | — | — | — | 1 | |
| Neoadjuvant ipilimumab + nivolumab | — | — | — | — | — | 1 | |
| Adjuvant nivolumab | — | — | — | — | — | 1 | |
| Transtympanic sodium thiosulphate (STS) 0.1M/0,5% hyaluronate | — | — | — | — | — | 1 | |
| botensilimab | — | — | — | — | — | 1 | |
| balstilimab | — | — | — | — | — | 1 | |
| FLOT | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | 15 | ||
| Ipilimumab | — | — | — | 11 | |||
| Pembrolizumab | — | — | — | — | — | 8 | |
| Atezolizumab | — | — | — | — | 5 | ||
| Paclitaxel and Carboplatin | — | — | — | — | — | 3 | |
| Paclitaxel | — | — | — | — | 6 | ||
| Docetaxel | — | — | — | — | 5 | ||
| Capecitabine | — | — | — | — | 3 | ||
| Olaparib | — | — | — | — | 5 | ||
| Lenvatinib | — | — | — | — | — | 2 | |
| Oxaliplatin | — | — | — | — | — | 2 | |
| Carboplatin | — | — | — | — | 5 | ||
| Erlotinib | — | — | — | — | 2 | ||
| Trametinib | — | — | — | — | — | 3 |
60 more active programs hidden
Next readouts
- 2018-12
- 2022-12-15
- 2023-01
- 2023-06
- 2024-01-01
- 2024-01-01
- 2024-01-12
- 2024-04-01
- 2024-07-18
- 2024-11-15
Top conditions
- Breast Cancer35
- Prostate Cancer11
- Head and Neck Cancer7
- Colorectal Cancer7
- Ovarian Cancer6
- Carcinoma, Non-Small-Cell Lung6
- NSCLC5
- Melanoma5
Frequently asked questions about The Netherlands Cancer Institute
- How many clinical trials does The Netherlands Cancer Institute have on ClinicalTrials.gov?
- The Netherlands Cancer Institute is listed as the lead sponsor on 228 clinical trials in ClinicalTrials.gov, 76 of which are currently active (recruiting, enrolling, or ongoing).
- How many of The Netherlands Cancer Institute's trials are in Phase 3?
- 32 of The Netherlands Cancer Institute's trials are in Phase 3, spread across 100 active drug programs.
- What therapeutic areas does The Netherlands Cancer Institute focus on?
- The Netherlands Cancer Institute's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Prostate Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer.
- When are The Netherlands Cancer Institute's next clinical trial readouts?
- The Netherlands Cancer Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2”, expected around 2018-12.